BIOXYTRAN, INC (BIXT)
BioXyTran, Inc. engages in the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans, which is a lack of oxygen in tissues. Its product pipeline includes BXT-25, a drug designed to oxygenate ischemic (reduced blood flow) regions in the brain that suffered from hypoxia during a brain stroke, and BXT-252, which treats chronic wounds resulting from ischemia caused by occlusion of capillaries. The company was founded on June 9, 2008 and is headquartered in Needham, MA.
Address
C/O BIOXYTRAN, INC.
NEEDHAM, MA 02494
Founded
2008
Number of Employees
-
Website
http://www.bioxytraninc.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)